Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease
NVA237 BID Versus Placebo Twelve-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01715298
- Testing
- NVA237
- Where
- 59 sites in United States
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT06527144
- Testing
- 3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation
- Where
- 28 sites in China
- Volunteers
- 240 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
Effect of Indacaterol on Inspiratory Capacity (IC)
This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive…
- Trial name
- NCT01012765
- Testing
- Indacaterol, Tiotropium
- Where
- 21 sites in Germany
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Remote Patient Monitoring in COPD Patients
Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.
The purpose of this pilot study is to evaluate a remote patient monitoring (RPM) system using a daily PRO tool (EXACT = Exacerbations of Chronic Pulmonary Disease Tool), in preventing hospitalization from Chronic Obstructive…
- Trial name
- PREMIERE (NCT01744028)
- Testing
- Remote Patient Monitoring, Usual care
- Where
- 20 sites in Spain, Sweden
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
- Trial name
- NCT00274534
- Testing
- Tiotropium, Salmeterol
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
COPD
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in: 1.
- Trial name
- NCT01948544
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- StratiHealth
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
To investigate the efficacy and safety of repeated dosing of Levalbuterol over 6 weeks of treatment in COPD.
- Trial name
- NCT00665600
- Testing
- Levalbuterol HCl, Albuterol Sulfate
- Where
- 24 sites in United States, Canada
- Volunteers
- 257 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04542057
- Testing
- Ensifentrine
- Where
- 130 sites in United States, Belgium and 8 more
- Volunteers
- 790 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD
The purpose of study is to evaluate the efficacy and safety of Benzalkonium Chloride Solution clearing the oral colonized bacterium in hospitalized patients with COPD.
- Trial name
- NCT02269800
- Testing
- Benzalkonium chloride solution, Normal saline
- Volunteers
- 60 people
- Sponsor
- Lustre Pharmaceutical Lab Co., Ltd
Chronic Obstructive Pulmonary Disease
A40 Expiratory Flow Limitation Registry
This prospective observational multicenter registry study will include adults greater than 40 years old, diagnosed with chronic obstructive pulmonary disease, requiring home noninvasive ventilation as part of standard medical…
- Trial name
- NCT04419428
- Testing
- BiPAP A40 Expiratory Flow Limitation (EFL)
- Where
- United Kingdom
- Sponsor
- Philips Clinical & Medical Affairs Global
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03118765
- Testing
- GSP304 (tiotropium bromide) Inhalation Solution, Spiriva® Respimat® inhalation spray
- Where
- 25 sites in United States
- Volunteers
- 155 people
- Sponsor
- Glenmark Specialty S.A.
Infection, Pulmonary Disease, Chronic Obstructive
Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder
The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients.
- Trial name
- NCT01168895
- Testing
- Cipro Inhale (Ciprofloxacin, BAYQ3939)
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
After screening, subjects will enter a 4 week open-label run-in period with fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg administered once daily via dry powder inhaler (DPI).
- Trial name
- NCT02119286
- Testing
- FF, VI, UMEC
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 620 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
- Trial name
- NCT04169529
- Testing
- Reveal LINQ
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
The prevalence, low cost, and low burden of wearable devices that provide quantitative and qualitative feedback on a subject's activity level present an opportunity for the use of these devices in clinical and observational…
- Trial name
- NCT02619357
- Testing
- SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01322594
- Testing
- MEDI2338
- Where
- 4 sites in South Africa, United Kingdom
- Volunteers
- 31 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.